Your browser doesn't support javascript.
Late Complications of COVID-19.
Roden, Anja C; Boland, Jennifer M; Johnson, Tucker F; Aubry, Marie Christine; Lo, Ying-Chun; Butt, Yasmeen M; Maleszewski, Joseph J; Larsen, Brandon T; Tazelaar, Henry D; Khoor, Andras; Smith, Maxwell L; Moua, Teng; Jenkins, Sarah M; Moyer, Ann M; Yi, Eunhee S; Bois, Melanie C.
  • Roden AC; From the Department of Laboratory Medicine and Pathology (Roden, Boland, Aubry, Lo, Maleszewski, Moyer, Yi, Bois), Mayo Clinic Rochester, Rochester, Minnesota.
  • Boland JM; From the Department of Laboratory Medicine and Pathology (Roden, Boland, Aubry, Lo, Maleszewski, Moyer, Yi, Bois), Mayo Clinic Rochester, Rochester, Minnesota.
  • Johnson TF; From the Department of Radiology (Johnson), Mayo Clinic Rochester, Rochester, Minnesota.
  • Aubry MC; From the Department of Laboratory Medicine and Pathology (Roden, Boland, Aubry, Lo, Maleszewski, Moyer, Yi, Bois), Mayo Clinic Rochester, Rochester, Minnesota.
  • Lo YC; From the Department of Laboratory Medicine and Pathology (Roden, Boland, Aubry, Lo, Maleszewski, Moyer, Yi, Bois), Mayo Clinic Rochester, Rochester, Minnesota.
  • Butt YM; From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Butt, Larsen, Tazelaar, Smith).
  • Maleszewski JJ; From the Department of Laboratory Medicine and Pathology (Roden, Boland, Aubry, Lo, Maleszewski, Moyer, Yi, Bois), Mayo Clinic Rochester, Rochester, Minnesota.
  • Larsen BT; From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Butt, Larsen, Tazelaar, Smith).
  • Tazelaar HD; From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Butt, Larsen, Tazelaar, Smith).
  • Khoor A; From the Department of Laboratory Medicine and Pathology, Mayo Clinic Florida, Jacksonville (Khoor).
  • Smith ML; From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Butt, Larsen, Tazelaar, Smith).
  • Moua T; From the Division of Critical Care and Pulmonary Medicine (Moua), Mayo Clinic Rochester, Rochester, Minnesota.
  • Jenkins SM; From the Department of Quantitative Health Sciences (Jenkins), Mayo Clinic Rochester, Rochester, Minnesota.
  • Moyer AM; From the Department of Laboratory Medicine and Pathology (Roden, Boland, Aubry, Lo, Maleszewski, Moyer, Yi, Bois), Mayo Clinic Rochester, Rochester, Minnesota.
  • Yi ES; From the Department of Laboratory Medicine and Pathology (Roden, Boland, Aubry, Lo, Maleszewski, Moyer, Yi, Bois), Mayo Clinic Rochester, Rochester, Minnesota.
  • Bois MC; From the Department of Laboratory Medicine and Pathology (Roden, Boland, Aubry, Lo, Maleszewski, Moyer, Yi, Bois), Mayo Clinic Rochester, Rochester, Minnesota.
Arch Pathol Lab Med ; 146(7): 791-804, 2022 07 01.
Article in English | MEDLINE | ID: covidwho-1912032
ABSTRACT
CONTEXT.­ Studies of lungs in patients with COVID-19 have focused on early findings. OBJECTIVE.­ To systematically study histopathologic and imaging features and presence of SARS-CoV-2 RNA in lung tissue from patients in later stages of COVID-19. DESIGN.­ Autopsies, explants, surgical lung biopsies, transbronchial biopsies, cryobiopsies, and needle biopsies from patients with COVID-19 whose onset of symptoms/confirmed diagnosis was more than 28 days before the procedure were studied. Available images were reviewed. Reverse transcription droplet digital polymerase chain reaction for SARS-CoV-2 RNA was performed on lung tissue. RESULTS.­ Of 44 specimens (43 patients; median age, 59.3 years; 26 [60.5%] male) features of acute lung injury (ALI) were seen in 39 (88.6%), predominantly organizing pneumonia and diffuse alveolar damage, up to 298 days after onset of COVID-19. Fibrotic changes were found in 33 specimens (75%), most commonly fibrotic diffuse alveolar damage (n = 22) and cicatricial organizing pneumonia (n = 12). Time between acquiring COVID-19 and specimen was shorter in patients with diffuse ALI (median, 61.5 days) compared with patients with focal (140 days) or no ALI (130 days) (P = .009). Sixteen (of 20; 80%) SARS-CoV-2 reverse transcription droplet digital polymerase chain reaction tests were positive, up to 174 days after COVID-19 onset. Time between COVID-19 onset and most recent computed tomography in patients with consolidation on imaging was shorter (median, 43.0 days) versus in patients without consolidation (87.5 days; P = .02). Reticulations were associated with longer time to computed tomography after COVID-19 onset (median, 82 versus 23.5 days; P = .006). CONCLUSIONS.­ ALI and SARS-CoV-2 RNA can be detected in patients with COVID-19 for many months. ALI may evolve into fibrotic interstitial lung disease.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Long Covid Limits: Female / Humans / Male / Middle aged Language: English Journal: Arch Pathol Lab Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Long Covid Limits: Female / Humans / Male / Middle aged Language: English Journal: Arch Pathol Lab Med Year: 2022 Document Type: Article